InnoCare IPO oversubscribed 300x as Hong Kong investors turned to biotech amid runoff
Forget the global stock meltdown. Or at least Chinese biotech InnoCare did, forging ahead with a more than $250-million IPO in Hong Kong despite …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.